51. Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus
- Author
-
Carlos A Guerrero-Bustamante, Katrina Ford, James Soothill, Kimberly Gilmour, Kathryn A. Harris, Daniel A. Russell, Rebekah M. Dedrick, Deborah Jacobs-Sera, Helen Spencer, Robert T. Schooley, Rebecca A. Garlena, and Graham F. Hatfull
- Subjects
0301 basic medicine ,Adolescent ,Cystic Fibrosis ,Mycobacterium Infections, Nontuberculous ,Drug resistance ,Mycobacterium abscessus ,Cystic fibrosis ,General Biochemistry, Genetics and Molecular Biology ,Article ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Drug Resistance, Bacterial ,medicine ,Humans ,Phage Therapy ,Disseminated mycobacterium abscessus infection ,biology ,business.industry ,Bilateral lung transplantation ,General Medicine ,biology.organism_classification ,medicine.disease ,Forward genetics ,3. Good health ,030104 developmental biology ,Lytic cycle ,030220 oncology & carcinogenesis ,Female ,Liver function ,business ,Genetic Engineering - Abstract
A 15-year-old patient with cystic fibrosis with a disseminated Mycobacterium abscessus infection was treated with a three-phage cocktail following bilateral lung transplantation. Effective lytic phage derivatives that efficiently kill the infectious M. abscessus strain were developed by genome engineering and forward genetics. Intravenous phage treatment was well tolerated and associated with objective clinical improvement, including sternal wound closure, improved liver function, and substantial resolution of infected skin nodules. Clinical use of engineered bacteriophages for the treatment of disseminated mycobacterial infection.
- Published
- 2019